Method of treating cancer using kinase inhibitors
First Claim
1. A method for treating a cancer that expresses functional epidermal growth factor receptors (EGFRs) in a patient resistant or non-responsive to a daily dose of EGFR-tyrosine kinase inhibitor selected from the group consisting of gefitinib and erlotinib, comprising:
- providing a resistance-surmounting quantity of a kinase inhibitor; and
administering the resistance-surmounting quantity of the kinase inhibitor to the patient at a time interval selected from the group consisting of once per week and twice per week,wherein the kinase inhibitor is selected from the group consisting of gefitinib or a pharmaceutically acceptable salt thereof, the resistance-surmounting quantity of the kinase inhibitor is at least 500 mg of the kinase inhibitor and the cancer is a type of cancer selected from the group consisting of prostate cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, ovarian cancer, and a glioblastoma tumor.
4 Assignments
0 Petitions
Accused Products
Abstract
Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual'"'"'s probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.
19 Citations
23 Claims
-
1. A method for treating a cancer that expresses functional epidermal growth factor receptors (EGFRs) in a patient resistant or non-responsive to a daily dose of EGFR-tyrosine kinase inhibitor selected from the group consisting of gefitinib and erlotinib, comprising:
-
providing a resistance-surmounting quantity of a kinase inhibitor; and administering the resistance-surmounting quantity of the kinase inhibitor to the patient at a time interval selected from the group consisting of once per week and twice per week, wherein the kinase inhibitor is selected from the group consisting of gefitinib or a pharmaceutically acceptable salt thereof, the resistance-surmounting quantity of the kinase inhibitor is at least 500 mg of the kinase inhibitor and the cancer is a type of cancer selected from the group consisting of prostate cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, ovarian cancer, and a glioblastoma tumor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A method for treating prostate cancer in a patient resistant or non-responsive to a daily dose of EGFR-tyrosine kinase inhibitor selected from the group consisting of gefitinib and erlotinib, comprising:
-
providing a resistance-surmounting quantity of gefitinib or a pharmaceutically acceptable salt thereof; and administering the resistance-surmounting quantity of the gefitinib or the pharmaceutically acceptable salt thereof at a time interval selected from the group consisting of once per week and twice per week, wherein the resistance-surmounting quantity of the gefitinib or the pharmaceutically acceptable salt thereof is at least 500 mg. - View Dependent Claims (11, 12, 13, 14, 15, 16)
-
-
17. A method for treating prostate cancer in a patient resistant or non-responsive to a daily dose of gefitinib or a pharmaceutically acceptable salt thereof, comprising:
-
providing a resistance-surmounting quantity of gefitinib or a pharmaceutically acceptable salt thereof; and administering the resistance-surmounting quantity of the gefitinib or the pharmaceutically acceptable salt thereof at a time interval selected from the group consisting of once per week and twice per week, wherein the resistance-surmounting quantity of the gefitinib or the pharmaceutically acceptable salt thereof is at least 500 mg. - View Dependent Claims (18, 19, 20, 21, 22, 23)
-
Specification